In this OncLiveTV video, watch Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology from the Jagiellonian University, Poland, talk about MOR208 for non-Hodgkin’s lymphoma treatments.
According to OncLive, MOR208 is “a monoclonal antibody directed against the antigen CD19” and it was “given to patients for at least 3 months.”
“The 30% response rate was more than expected,” Jurczak stated.
Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?